MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Cancer Epidemiology and Prevention

Schottenfeld, D. (2006) · doi:10.1093/acprof:oso/9780195149616.001.0001 · Cited by 3,376

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069

Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma

Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 579

Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology

M�ller, A. M. S., Ihorst, G., Mertelsmann, R. H., & Engelhardt, M. M. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0939-7 · Cited by 495

Steroid hormone receptors in breast cancer management

Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438

Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer

Li, C. I. (2003) · JAMA · doi:10.1001/jama.289.24.3254 · Cited by 415

MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310

Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309

Hartmann, E., Fernández, V., Stöcklein, H., Hernández, L., Campo, E., & Rosenwald, A. (2007) · Haematologica · doi:10.3324/haematol.10891 · Cited by 32

A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer

Kulkarni, D. A., Vázquez, A., Haffty, B. G., Bandera, E. V., Hu, W., Sun, Y., Toppmeyer, D., Levine, A. J., & Hirshfield, K. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp224 · Cited by 33

Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson

Menéndez, D., Inga, A., Jordan, J. J., & Resnick, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210277 · Cited by 32

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

Gansmo, L. B., Knappskog, S., Romundstad, P., Hveem, K., VATTEN, L. J., & Lønning, P. E. (2014) · International Journal of Cancer · doi:10.1002/ijc.29358 · Cited by 31

MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis

Li, Y., Zhao, H., Sun, L. J., Huang, L., Yang, Q., & Kong, B. (2011) · Human Cell · doi:10.1007/s13577-011-0013-4 · Cited by 28

The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies

Antoniou, N. G., Lаgopati, N., Balourdas, D.-I., Nikolaou, M., Papalampros, A., Vasileiou, P. V. S., Myrianthopoulos, V., Kotsinas, A., Shiloh, Y., Liontos, M., et al. (2019) · Cancers · doi:10.3390/cancers12010062 · Cited by 28

Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li–Fraumeni syndrome

Wu, C., Krahe, R., Lozano, G., Zhang, B., Wilson, C. D., Jo, E.-J., Amos, C. I., Shete, S. S., & Strong, L. C. (2011) · Human Genetics · doi:10.1007/s00439-011-0957-1 · Cited by 29

Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus.

Pan, Q., Chen, J., Guo, L., Lü, X., Liao, S., Zhao, C., Wang, S., & Liu, J. (2019) · Europe PMC (PubMed Central) · Cited by 29

Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer

Sun, Y.-F., Leu, J., Chen, S.-M., Lin, I., & Lee, Y. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-13 · Cited by 28

Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/ -catenin genes in human herpesvirus 8-associated primary effusion lymphoma

Boulanger, E., Marchio, A., Hong, S. S., & Pineau, P. (2009) · Haematologica · doi:10.3324/haematol.2009.007260 · Cited by 28

MDM2SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk

Krekac, D., Hrazdilová, K., Knoflíčková, D., Hrstka, R., Müller, P., Nenutil, R., & Vojtěšek, B. (2008) · Oncology · doi:10.1159/000139135 · Cited by 27

Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma

Schuetz, J. M., Daley, D., Graham, J., Berry, B. R., Gallagher, R. P., Connors, J. M., Gascoyne, R. D., Spinelli, J. J., & Brooks-Wilson, A. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031560 · Cited by 28

Transcriptional Responses to Estrogen and Progesterone in Mammary Gland Identify Networks Regulating p53 Activity

Lu, S., Becker, K. A., Hagen, M. J., Yan, H., Roberts, A. L., Mathews, L., Schneider, S. S., Siegelmann, H. T., MacBeth, K. J., Tirrell, S. M., et al. (2008) · Endocrinology · doi:10.1210/en.2008-0035 · Cited by 27

TP 53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients

Vuolo, V. D., Buonaguro, L., Izzo, F., Losito, S., Botti, G., Buonaguro, F. M., & Tornesello, M. L. (2011) · Infectious Agents and Cancer · doi:10.1186/1750-9378-6-13 · Cited by 27

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer

Yoneda, T., Kuboyama, A., Kato, K., Ohgami, T., Okamoto, K., Saito, T., & Wake, N. (2013) · Oncology Reports · doi:10.3892/or.2013.2433 · Cited by 26

Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls

Zhuo, W., Zhang, L., Zhu, B., Ling, J., & Chen, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041546 · Cited by 25

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

Gansmo, L. B., VATTEN, L. J., Romundstad, P., Hveem, K., Ryan, B. M., Harris, C. C., Knappskog, S., & Lønning, P. E. (2016) · Oncotarget · doi:10.18632/oncotarget.8705 · Cited by 26

Untitled work

(2008) · PubMed · Cited by 26

Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes

Mehta, M. S., Dolfi, S. C., Bronfenbrener, R., Bilal, E., Chen, C., Moore, D. F., Lin, Y., Rahim, H. M., Aisner, S. C., Kersellius, R. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069851 · Cited by 26

An Updated Meta-Analysis on the Association of MDM2 SNP309 Polymorphism with Colorectal Cancer Risk

Qin, X. Y., Peng, Q., Tang, W., Lao, X., Chen, Z., Lai, H., Deng, Y., Mo, C., Sui, J., Wu, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076031 · Cited by 26

Natural selection and functional genetic variation in the p53 pathway

Sucheston, L., Witonsky, D., Hastings, D., Yildiz, O., Clark, V. J., Rienzo, A. D., & Onel, K. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr028 · Cited by 27

Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway

Kundu, N., Brekman, A., Kim, J. Y., Xiao, G., Gao, C., & Bargonetti, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18147 · Cited by 26

MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients

Tornesello, M. L., Buonaguro, L., Cristillo, M., Biryahwaho, B., Downing, R. G., Hatzakis, A., Alessi, E., Cusini, M., Ruocco, V., Viviano, E., et al. (2010) · Biomarkers · doi:10.3109/1354750x.2010.525664 · Cited by 24

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy

Shinohara, A., Sakano, S., Hinoda, Y., Nishijima, J., Kawai, Y., Misumi, T., Nagao, K., Hara, T., & Matsuyama, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01331.x · Cited by 25

MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group

Phillips, C. L., Gerbing, R. B., Alonzo, T. A., Perentesis, J. P., Harley, I. T. W., Meshinchi, S., Bhatla, D., Radloff, G. A., & Davies, S. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22519 · Cited by 25

Association between polymorphisms in cell cycle genes and advanced prostate carcinoma

Kibel, A. S., Jin, C. H., Klim, A., Luly, J. R., Roehl, K. A., Wu, W. S., & Suarez, B. K. (2008) · The Prostate · doi:10.1002/pros.20784 · Cited by 28

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)

Knappskog, S., Gansmo, L. B., Dibirova, K., Metspalu, A., Cybulski, C., Peterlongo, P., Aaltonen, L. A., VATTEN, L. J., Romundstad, P., Hveem, K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1910 · Cited by 24

The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation

Kung, C.-P., Liu, Q., & Murphy, M. E. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323595 · Cited by 24

Recent Natural Selection Identifies a Genetic Variant in a Regulatory Subunit of Protein Phosphatase 2A that Associates with Altered Cancer Risk and Survival

Grochola, L. F., Vázquez, A., Bond, E. E., Würl, P., Taubert, H. W., Müller, T. H., Levine, A. J., & Bond, G. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0797 · Cited by 24

Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors

Chien, W.-P., Wong, R., Cheng, Y., Chen, C., & Lee, H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0853-2 · Cited by 24

An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients

Atwal, G. S., Rabadán, R., Lozano, G., Strong, L. C., Ruijs, M., Schmidt, M. K., Veer, L. J. V., Nevanlinna, H. A., Tommiska, J., Aittomäki, K., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001951 · Cited by 24

Impact ofMDM2single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma

Nakashima, M., Kondo, S., Shimizu, Y., Wakisaka, N., Murono, S., Furukawa, M., & Yoshizaki, T. (2008) · Acta Oto-Laryngologica · doi:10.1080/00016480701724904 · Cited by 24

No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin

Wilkening, S., Hemminki, K., Rudnai, P., Gurzau, E. S., Koppová, K., Försti, A., & Kumar, R. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07994.x · Cited by 24

p53 Is Not Required for High CIN to Induce Tumor Suppression

Hrycyniak, L., Wan, J., Ryan, S. D., Kaur, C., Sullivan, R., Roopra, A., & Weaver, B. A. A. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0488 · Cited by 21

TCDD mediates inhibition of p53 and activation of ERα signaling in MCF-7 cells at moderate hypoxic conditions

Seifert, B. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000354 · Cited by 23

MDM2 gene SNP309 T/G and p53gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians

Bittenbring, J. T., Parisot, F., Wabo, A., Monika, M., Kerschenmeyer, L., Kreuz, M., Trümper, L. H. P., Landt, O., Menzel, A., Pfreundschuh, M. G., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-116 · Cited by 23

The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review

Jiang, H., Luo, J., & Lei, H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2021.108910 · Cited by 23

MSH2 −118T>C and MSH6 −159C>T promoter polymorphisms and the risk of colorectal cancer

Mrkonjic, M., Raptis, S., Green, R. C., Monga, N., Daftary, D., Dicks, E. L., Younghusband, H. B., Parfrey, P. S., Gallinger, S., McLaughlin, J. R., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm229 · Cited by 23

Constitutive and induced functions of the p53 gene

Zheltukhin, A. O., & Chumakov, P. M. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910130110 · Cited by 23

Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity

Haupt, S., & Haupt, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.632719 · Cited by 22

MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis

Peng, Q., Mo, C., Qin, A., Lao, X., Chen, Z., Sui, J., Wu, J., Zhai, L., Yang, S., Qin, X. Y., et al. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-85 · Cited by 21

Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics

Stoehr, R., Hitzenbichler, F., Kneitz, B., Hammerschmied, C. G., Bürger, M., Tannapfel, A., & Hartmann, A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604441 · Cited by 21

Significance of MDM2 and P14ARF polymorphisms in susceptibility to differentiated thyroid carcinoma

Zhang, F., Xu, L., Wei, Q., Song, X., Sturgis, E. M., & Li, G. (2012) · Surgery · doi:10.1016/j.surg.2012.11.009 · Cited by 21

An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia

Godley, L. A., Cunningham, J. M., Dolan, M. E., Huang, R. S., Gurbuxani, S. K., McNerney, M. E., Larson, R. A., Leong, H., Lussier, Y. A., Onel, K., et al. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.003 · Cited by 21

Panels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: their dependence on age, gender and clinical stages

Chian, C., Hwang, Y.-T., Terng, H.-J., Lee, S.-C., Chao, T.-Y., Chang, H., Ho, C., Wu, Y., & Perng, W. (2016) · Oncotarget · doi:10.18632/oncotarget.10558 · Cited by 22

Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis

Chen, Y., Chang, Y., Chang, J., & Wu, S. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2416-y · Cited by 21

A role for biomarkers in the screening and diagnosis of breast cancer in younger women

Esserman, L. J., Shieh, Y., Park, J. W., & Ozanne, E. M. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.5.533 · Cited by 21

MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer

Ryan, B. M., Calhoun, K. M., Pine, S. R., Bowman, E. D., Robles, A. I., Ambs, S., & Harris, C. C. (2012) · International Journal of Cancer · doi:10.1002/ijc.27573 · Cited by 20

Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene

Mittelstraß, K., Sauter, W., Rosenberger, A., Illig, T., Timofeeva, M. N., Klopp, N., Dienemann, H., Meese, E. U., Sybrecht, G. W., Woelke, G., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-113 · Cited by 20

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

Gansmo, L. B., Bjørnslett, M., Halle, M. K., Salvesen, H. B., Romundstad, P., Hveem, K., VATTEN, L. J., Dørum, A., Lønning, P. E., & Knappskog, S. (2017) · BMC Cancer · doi:10.1186/s12885-017-3094-y · Cited by 20

Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women

Zając, A. E., Stachowiak, G., Pertyński, T., Romanowicz, H., Wilczyński, J. R., & Smolarz, B. (2013) · Polish Journal of Pathology · doi:10.5114/pjp.2012.32776 · Cited by 19

A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients

Pan, X., Li, Y., Feng, J., Wang, X., Bo, H., Shi, R., & Zhang, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-126 · Cited by 19

Identification of functional DNA variants in the constitutive promoter region of MDM2

Lalonde, M., Ouimet, M., Larivière, M., Kritikou, E. A., & Sinnett, D. (2012) · Human Genomics · doi:10.1186/1479-7364-6-15 · Cited by 19

MDM2 SNP309 polymorphism is associated with colorectal cancer risk

Wang, W., Du, M., Gu, D., Zhu, L., Chu, H., Tong, N., Zhang, Z., Xu, Z., & Wang, M. (2014) · Scientific Reports · doi:10.1038/srep04851 · Cited by 19

Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer

Zhang, J., Zhang, Y., & Zhang, Z. (2018) · Medicine · doi:10.1097/md.0000000000009554 · Cited by 18

Splice Variants of MDM2 in Oncogenesis

Rosso, M., Okoro, D. R., & Bargonetti, J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_14 · Cited by 18

MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

Hav, M., Libbrecht, L. J., Ferdinande, L., Pattyn, P., Laurent, S., Peeters, M., Praet, M. M., & Pauwels, P. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-1012-7 · Cited by 18

MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset

Hamid, S., Yang, Y., Karen‐Ng, L. P., Ismail, S. M., Zain, R. B., Lim, K. P., Mustafa, W. M. W., Abraham, M. T., Teo, S., & Cheong, S. C. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.06.003 · Cited by 17

Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells

Liu, B., Song, J., Han, H., Hu, Z., Chen, N., Cui, J. Z., Matsubara, J. A., Zhong, J., & Lei, H. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0307-9 · Cited by 17

MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer

Li, X., Han, X., Liu, R., Wang, Z., Li, H., Chen, Q., Zhang, P., Wang, Z., & Chong, T. (2015) · Oncotarget · doi:10.18632/oncotarget.3923 · Cited by 17

Lack of Association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults

Onel, K. B., Huo, D., Hastings, D., Fryer-Biggs, J., Crow, M., & Onel, K. B. (2008) · Lupus · doi:10.1177/0961203308094558 · Cited by 17

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer

Helwa, R., Gansmo, L. B., Romundstad, P., Hveem, K., VATTEN, L. J., Ryan, B. M., Harris, C. C., Lønning, P. E., & Knappskog, S. (2016) · Scientific Reports · doi:10.1038/srep33153 · Cited by 16

Age‐dependent association of MDM2 promoter polymorphisms and uterine leiomyoma in S outh‐ E ast I ran: A preliminary report

Salimi, S., Hajizadeh, A., Khodamian, M., Pejman, A., Fazeli, K., & Yaghmaei, M. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12625 · Cited by 16

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer

Lee, Y.-J. (2011) · Oncology Reports · doi:10.3892/or.2011.1254 · Cited by 15

Liver‐specific expression of p53‐negative regulator mdm2 leads to growth retardation and fragile liver in zebrafish

Chen, L.-J., Hsu, C., Hong, J., Jou, L.-K., Tseng, H., Wu, J., Liou, Y., & Her, G. M. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21477 · Cited by 16

MDM2 T309G has a Synergistic Effect with P21 ser31arg Single Nucleotide Polymorphisms on the Risk of Acute Myeloid Leukemia

Ebid, G., Sidhom, I., Gammal, M. M. E., & Moneer, M. M. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.9.4315 · Cited by 16

No association of MDM2 SNP309 with risk of glioblastoma and prognosis

Hallani, S. E., Marie, Y., Idbaïh, A., Rodero, M. P., Boisselier, B., Laigle–Donadey, F., Ducray, F., Delattre, J., & Sanson, M. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9416-1 · Cited by 15

MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast‐free survival in chronic phase patients receiving imatinib

Liu, Y., Hsiao, H., Yang, W., Liu, T., Chang, C., Yang, M., Lin, P., Hsu, J.-F., Lee, C., & Lin, S. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22061 · Cited by 15

MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population

Loo, L. W. M., Gao, C., Shvetsov, Y. B., Okoro, D. R., Hernandez, B. Y., & Bargonetti, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5065-7 · Cited by 15

Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study

Miedl, H., Lebhard, J., Ehart, L., & Schreiber, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030509 · Cited by 14

A pooled analysis of molecular epidemiological studies on modulation of DNA repair by host factors

Opattová, A., Langie, S. A. S., Milić, M., Collins, A. R., Brevik, A., Coşkun, E., Dušinská, M., Gaivão, I., Kadıoğlu, E., Laffón, B., et al. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2022.503447 · Cited by 15

A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence

Surakhy, M., Wallace, M. D., Bond, E. E., Grochola, L. F., Perez, H., Giovannantonio, M. D., Zhang, P., Malkin, D. M., Carter, H. K., Parise, I. Z. S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0764-3 · Cited by 15

Pathways Contributing to Development of Spontaneous Mammary Tumors in BALB/c-Trp53+/− Mice

Yan, H., Blackburn, A. C., McLary, S. C., Tao, L., Roberts, A. L., Xavier, E. A., Dickinson, E. S., Seo, J. H., Arenas, R. B., Otis, C. N., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090438 · Cited by 13

Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta‐analysis

Liu, G., Jiang, D., Shen, S., & Yu, L. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03067.x · Cited by 14

Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls

Dai, Z.-J., Gao, J., Kang, A.-J., Lin, S., Zhang, S.-Q., Liu, D., Zhao, Y., Yang, P., Wang, M., & Wang, X.-J. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s60680 · Cited by 15

MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness

Capasso, M., Ayala, F., Avvisati, R. A., Russo, R., Gambale, A., Mozzillo, N., Ascierto, P. A., & Iolascon, A. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.62 · Cited by 14

Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers

Fang, S., Krahe, R., Bachinski, L. L., Zhang, B., Amos, C. I., & Strong, L. C. (2011) · Human Genetics · doi:10.1007/s00439-011-1039-0 · Cited by 14

Potential of Advexin ® : A p53 Gene-Replacement Therapy in Li–Fraumeni Syndrome

Nemunaitis, J., & Nemunaitis, J. J. (2008) · Future Oncology · doi:10.2217/14796694.4.6.759 · Cited by 14

Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women

Floris, M., Pira, G., Castiglia, P., Idda, M. L., Steri, M., Miglio, M. R. D., Piana, A. F., Cossu, A., Azara, A., Arru, C., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13451 · Cited by 12

Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk

Enokida, Y., Shimizu, K., Kakegawa, S., Atsumi, J., Takase, Y., Miyamae, Y., Nagashima, T., Ohtaki, Y., Kaira, K., Sunaga, N., et al. (2014) · Biomedical Reports · doi:10.3892/br.2014.305 · Cited by 13

Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore

Koh, W., Berg, D. V. D., Jin, A., Wang, R., Yuan, J., & Yu, M. C. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1680-2 · Cited by 13

The MDM2 309T>G Polymorphism and Ovarian Cancer Risk: A Meta-Analysis of 1534 Cases and 2211 Controls

Ma, Y., Guan, T., Yao, H., Yu, S., Chen, L., Xia, Y., He, X., Wang, H., Jiang, X., & Tao, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055019 · Cited by 13

Benign SNPs in the Coding Region of TP53 : Finding the Needles in a Haystack of Pathogenic Variants

Soussi, T. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0172 · Cited by 13

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers

Bjørnslett, M., Knappskog, S., Lønning, P. E., & Dørum, A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-454 · Cited by 13

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Elter, T., Kilp, J., Borchmann, P., Schulz, H., Hallek, M. J., & Engert, A. (2008) · Haematologica · doi:10.3324/haematol.13379 · Cited by 13

Do CDKN2 p16 540 C>G , CDKN2 p16 580 C>T , and MDM2 SNP309 T>G Gene Variants Act on Colorectal Cancer Development or Progression?

Tuna, G., Küçükhüseyin, Ö., Arıkan, S., Saglam, E. K., Güler, E., Cacına, C., Öztop, Ö., Turan, S., Korkmaz, G., & Yaylım, İ. (2013) · DNA and Cell Biology · doi:10.1089/dna.2012.1933 · Cited by 12

The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis

Yang, J., Gao, W., Song, N., Wang, W., Zhang, J.-X., Lu, P., Hua, L., & Gu, M. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2012.65 · Cited by 12

MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors

Sun, S. Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113638 · Cited by 12

Mdm2 and MdmX Involvement in Human Cancer

Berberich, S. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_15 · Cited by 12

Decreased Mdm2 Expression Inhibits Tumor Development and Extends Survival Independent of Arf and Dependent on p53

Eischen, C. M., & Boyd, K. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046148 · Cited by 12

Association between genetic polymorphisms in apoptosis-related genes and risk of cutaneous melanoma in women and men

de Oliveira, C., Lourenço, G. J., Rinck‐Junior, J. A., Cintra, M. L., de Moraes, A. M., & Lima, C. S. P. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.12.010 · Cited by 12

Human genetic variation and the risk of hepatocellular carcinoma development

Ezzikouri, S., Benjelloun, S., & Pineau, P. (2013) · Hepatology International · doi:10.1007/s12072-013-9463-y · Cited by 11

Evaluation of Single Nucleotide Polymorphisms (SNPs) in the p53 Binding Protein 1 (TP53BP1) Gene in Breast Cancer Patients Treated With Breast-Conserving Surgery and Whole-Breast Irradiation (BCS + RT)

Haffty, B. G., Goyal, S., Kulkarni, D. A., Green, C., Vazquez, A., Schiff, D. S., Moran, M. S., Yang, Q., Ganesan, S., & Hirshfield, K. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.02.005 · Cited by 11

No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes

Jaboin, J. J., Hwang, M., Perez, C. A., Cooper, C., Chen, H., Ye, C., Cai, Q., Wills, M. L., & Lü, B. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.031 · Cited by 11

Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population

Li, W., Wang, S. S., Deng, J., & Tang, J. X. (2017) · Oncology Letters · doi:10.3892/ol.2017.6327 · Cited by 10

Investigation of the Effect of MDM2 SNP309 and TP53 Arg72Pro Polymorphisms on the Age of Onset of Cutaneous Melanoma

Cotignola, J., Chou, J. F., Roy, P., Mitra, N., BUSAM, K. J., Halpern, A. C., & Orlow, I. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.15 · Cited by 11

Impact of the Mdm2SNP309-G allele on a murine model of colorectal cancer

Zhang, X., Pageon, L. R., & Post, S. M. (2014) · Oncogene · doi:10.1038/onc.2014.377 · Cited by 11

Prognostic Impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

Post, S. M., Pant, V., Abbas, H. A., & Quintás‐Cardama, A. (2010) · Oncotarget · doi:10.18632/oncotarget.123 · Cited by 11

TP53*P72 Allele Influences Negatively Female Life Expectancy in a Population of Central Italy: Cross-Sectional Study and Genetic-Demographic Approach Analysis

Pietro, F. D., Dato, S., Carpi, F. M., Corneveaux, J. J., Serfaustini, S., Maoloni, S., Mignini, F., Huentelman, M. J., Passarino, G., & Napolioni, V. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls223 · Cited by 11

A comprehensive evaluation of single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Asian populations: A systematic review and network meta-analysis

Zhang, C., Ye, Z., Zhang, Z., Zheng, J., Tang, Y.-M., Hou, E., Huang, Z., & Li, M. (2020) · Gene · doi:10.1016/j.gene.2020.144365 · Cited by 11

MDM2 SNP309 accelerates colorectal tumour formation in women

Bond, G. L., Menin, C., Bertorelle, R., Alhopuro, P., Aaltonen, L. A., & Levine, A. J. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.043539 · Cited by 97

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265

A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells

Hu, W., Feng, Z., Ma, L., Wagner, J., Rice, J. J., Stolovitzky, G. A., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2656 · Cited by 114

A mechanistic study of functional polymorphisms in the MDM2 gene

Solbakken, M. H. (2008) · NORA - Norwegian Open Research Archives

Die G/G-Variante des SNP309 im mdm2 Gen ist mit einem früheren Tumorentstehen in Nierenzellkarzinom-Patientinnen assoziiert

Stoehr, R., Wenners, A. S., Hartmann, A., Bertz, S., Spath, Walter, B., Junker, K., Moch, H., Hintze, R., Denzinger, S., et al. (2016) · German Medical Science (German Research Foundation) · doi:10.3205/16urobay047